These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16493252)

  • 1. Consolidation therapy in ovarian cancer: where do we stand?
    Dearnley DD; McMeekin DS
    Curr Opin Obstet Gynecol; 2006 Feb; 18(1):3-7. PubMed ID: 16493252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies for recurrent ovarian cancer management.
    Bhoola SM; Alvarez RD
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):437-48. PubMed ID: 15161442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer.
    Jalal SI; Ademuyiwa FO; Hanna NH
    Curr Opin Oncol; 2009 Mar; 21(2):110-5. PubMed ID: 19532011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.
    Möbus V; Kieback DG; Kaubitzsch SK
    Anticancer Res; 2007; 27(3B):1581-7. PubMed ID: 17595779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intraperitoneal chemotherapy for ovarian cancer].
    Noma J; Yoshida N
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer.
    Sugarbaker PH
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):15-24. PubMed ID: 19124999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance or consolidation therapy in advanced ovarian cancer.
    Pectasides D; Pectasides E
    Oncology; 2006; 70(5):315-24. PubMed ID: 17164587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pros and cons for systemic therapy in recurrent ovarian cancer.
    Oskay-Ozcelik G; Sehouli J
    Anticancer Res; 2009 Jul; 29(7):2831-6. PubMed ID: 19596970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive surgery for recurrent ovarian cancer.
    Hauspy J; Covens A
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):15-21. PubMed ID: 17218846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature.
    Tropé C; Kaern J
    J Clin Oncol; 2007 Jul; 25(20):2909-20. PubMed ID: 17617522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal chemotherapy for ovarian cancer.
    Hamilton CA; Berek JS
    Curr Opin Oncol; 2006 Sep; 18(5):507-15. PubMed ID: 16894301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of recurrent ovarian carcinoma: current status and future directions.
    Martin LP; Schilder RJ
    Semin Oncol; 2009 Apr; 36(2):112-25. PubMed ID: 19332246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
    Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
    Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal chemotherapy in ovarian cancer: an update.
    Runowicz CD
    Cancer J; 2008; 14(1):7-9. PubMed ID: 18303475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer: a focus on management of recurrent disease.
    Herzog TJ; Pothuri B
    Nat Clin Pract Oncol; 2006 Nov; 3(11):604-11. PubMed ID: 17080178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
    Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
    Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.